Abstracts tagged "Biologic agents and rheumatoid arthritis (RA)"

Abstract Number: 1466 • 2013 ACR/ARHP Annual Meeting
Survival On Treatment Of The Second Line Biologic Therapy: Switch Or Swap Strategy?
Ennio G. Favalli¹, Martina Biggioggero², Antonio Marchesoni³ and Pier Luigi Meroni², ¹Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, Milan, Italy, ²Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, ³UOC Day Hospital Rheumatology, Gaetano Pini Institute, Milan, Italy, Milano, Italy
Background/Purpose: The strategy for the choice of the second biologic agent after the failure of the first TNF inhibitor is still an unclear aspect in…
Abstract Number: 501 • 2013 ACR/ARHP Annual Meeting
A Randomized Placebo-Controlled Phase 2 Study To Evaluate Efficacy, Safety and Tolerability Of Two Secukinumab Loading Dose Regimens In Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate
Silvano Adami¹, André Beaulieu², Proton Rahman³, Bruno Seriolo⁴, Janet S. Lee⁵, Gerhard Krammer⁶, Brian Porter⁵, Anuradha Thulasiraman⁶ and Hanno B. Richards⁷, ¹Rheumatology Department, University of Verona, Verona, Italy, ²Faculty of Medicine, Laval University, Quebec, QC, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁵Novartis Pharma AG, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
A Randomized Placebo-Controlled Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Two Secukinumab Loading Dose Regimens in Subjects with Active Rheumatoid Arthritis Despite…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].